High-throughput screening-driven lead discovery: Meeting the challenges of finding new therapeutics

被引：0

作者：

Posner, BA ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, New Leads Biol Exploratory Med Sci, Groton Labs, Groton, CT 06340 USA

来源：

CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT | 2005年 / 8卷 / 04期

关键词：

ADME; high-throughput screening; lead discovery; medicinal chemistry; toxicology; virtual screening;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The pharmaceutical industry faces a number of challenges that have cumulatively led to a decline in productivity, despite increasing levels of investment in research and development. It is in this context that some researchers and business analysts are questioning the value of the high-throughput screening (HTS) paradigm for the discovery of new therapeutics. While this criticism may be premature, significant changes are occurring in HTS-driven lead discovery to address the failure of drug candidates in the clinic. This article highlights some of these changes and their potential impact.

引用

页码：487 / 494

页数：8